Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation (NASDAQ: ADAP) is a biotechnology company that develops diagnostic and therapeutic products based on its proprietary immune medicine platform. The company's website is www.adaptivebiotech.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Adaptive Biotechnologies Corp does
In the company’s own words
Adaptive Biotechnologies Corporation (NASDAQ: ADAP) is a biotechnology company that develops diagnostic and therapeutic products based on its proprietary immune medicine platform. The company's website is www.adaptivebiotech.com.
The company operates through two primary business segments: the MRD (Minimal Residual Disease) business and the Immune Medicine (IM) business. The MRD business generates the majority of revenue and focuses on clonoSEQ, a next-generation sequencing-based diagnostic test that detects and monitors minimal residual disease in patients with hematologic malignancies including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, diffuse large B cell lymphoma, and mantle cell lymphoma. clonoSEQ is the first and only FDA-authorized test for MRD detection in multiple lymphoid cancers and represents the company's core clinical diagnostic offering. The company also provides clonoSEQ assay services to biopharmaceutical partners for use in clinical drug development trials. The IM business leverages the company's immunosequencing technology to offer immune receptor sequencing services, proprietary data licensing, TCR-antigen prediction models, and target discovery capabilities to research and development partners.
Adaptive's immunosequencing platform combines proprietary chemistry, computational biology, and machine learning to decode the adaptive immune system by sequencing T cell receptors and B cell receptors at scale. The company has built a dynamic clinical immunomics database containing over 100,000 disease signatures and more than five million TCR-to-antigen matches across diverse antigens and HLA types.
The company maintains CLIA-certified, CAP-accredited, and ISO 13485-certified laboratory facilities in Seattle, Washington and South San Francisco, California. As of December 31, 2025, Adaptive held 416 issued and allowed patents and 64 pending patent applications protecting its immune medicine platform and applications. The company's intellectual property portfolio covers sequencing methods, diagnostic and prognostic tools, therapeutic antibodies, and disease-specific T cell receptors.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 1478320
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Adaptive Biotechnologies Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Adaptive Biotechnologies Corp · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Adaptive Biotechnologies Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Adaptive Biotechnologies Corp’s bonds, as funds hold them
Funds report holding 1 issues of Adaptive Biotechnologies Corp’s debt, $1.98M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.00%, maturing 2031 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Adaptive Biotechnologies Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Adaptive Biotechnologies Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Adaptive Biotechnologies Corp's last four quarterly filings that the numbers alone won't show?”